Purpose: To evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone metabolism and bone mineral density (BMD) in both HIV-infected men and women treated with highly active antiretroviral therapy (HAART). Method: We performed a 52-week prospective, multicenter, randomized, open-label clinical trial. Eligible participants were on stable HAART and had BMD values at the femoral neck or lumbar spine that corresponded to a t score less than -1. Patients were randomized to receive alendronate 70 mg weekly or no alendronate; calcium 1000 mg daily and vitamin D 500 IU daily were provided to all study recipients. Primary endpoint of the study was the change in bone metabolism evaluated by N-telopeptide of type 1 collagen and bone-specific alkaline phosphatase; the secondary endpoint was BMD variation. Results: 18 patients were randomized to the alendronate and 23 to the no-alendronate group (controls). The alendronate-treatment group compared to controls had a significant decrease in serum N-telopeptides, 1914 +/- 1433.4 vs. 3967 +/- 1650.5 pM/L (p = .005) after 1 year. Lumbar spine BMD increased by 4% in the alendronate group (p = .004) vs. 3.7% (p = .062) in controls, compared to baseline values. Femoral neck BMD decreased by 0.5% in the alendronate group (p = .05) and by 3.5% in the control group (p = .04). No between-groups differences for BMD were found (Delta lumbar-BMD 0.0351 +/- 0.0406 in cases and 0.0356 +/- 0.073 in controls [p = .9771, Delta femoral-BMD -0.085 +/- 0.160 in cases and -0.100 +/- 0.165 in controls [p = .795]). Conclusion: Alendronate plus vitamin D and calcium was effective in reducing bone resorption. Alendronate improved lumbar BMD and minimized femoral BMD decrease after 52 weeks compared to treatment with vitamin D and calcium alone in patients on HAART with osteopenia/osteoporosis.

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis / Guaraldi, Giovanni; G., Orlando; G., Madeddu; F., Vescini; Ventura, Paolo; S., Campostrini; M. S., Mura; N., Parise; R., Caudarella; Esposito, Roberto. - In: HIV CLINICAL TRIALS. - ISSN 1528-4336. - STAMPA. - 5:5(2004), pp. 269-277. [10.1310/MD8V-5DLG-EN3T-BRHX]

Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis

GUARALDI, Giovanni;VENTURA, Paolo;ESPOSITO, Roberto
2004

Abstract

Purpose: To evaluate the effects of alendronate, vitamin D, and calcium supplementation on bone metabolism and bone mineral density (BMD) in both HIV-infected men and women treated with highly active antiretroviral therapy (HAART). Method: We performed a 52-week prospective, multicenter, randomized, open-label clinical trial. Eligible participants were on stable HAART and had BMD values at the femoral neck or lumbar spine that corresponded to a t score less than -1. Patients were randomized to receive alendronate 70 mg weekly or no alendronate; calcium 1000 mg daily and vitamin D 500 IU daily were provided to all study recipients. Primary endpoint of the study was the change in bone metabolism evaluated by N-telopeptide of type 1 collagen and bone-specific alkaline phosphatase; the secondary endpoint was BMD variation. Results: 18 patients were randomized to the alendronate and 23 to the no-alendronate group (controls). The alendronate-treatment group compared to controls had a significant decrease in serum N-telopeptides, 1914 +/- 1433.4 vs. 3967 +/- 1650.5 pM/L (p = .005) after 1 year. Lumbar spine BMD increased by 4% in the alendronate group (p = .004) vs. 3.7% (p = .062) in controls, compared to baseline values. Femoral neck BMD decreased by 0.5% in the alendronate group (p = .05) and by 3.5% in the control group (p = .04). No between-groups differences for BMD were found (Delta lumbar-BMD 0.0351 +/- 0.0406 in cases and 0.0356 +/- 0.073 in controls [p = .9771, Delta femoral-BMD -0.085 +/- 0.160 in cases and -0.100 +/- 0.165 in controls [p = .795]). Conclusion: Alendronate plus vitamin D and calcium was effective in reducing bone resorption. Alendronate improved lumbar BMD and minimized femoral BMD decrease after 52 weeks compared to treatment with vitamin D and calcium alone in patients on HAART with osteopenia/osteoporosis.
2004
5
5
269
277
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis / Guaraldi, Giovanni; G., Orlando; G., Madeddu; F., Vescini; Ventura, Paolo; S., Campostrini; M. S., Mura; N., Parise; R., Caudarella; Esposito, Roberto. - In: HIV CLINICAL TRIALS. - ISSN 1528-4336. - STAMPA. - 5:5(2004), pp. 269-277. [10.1310/MD8V-5DLG-EN3T-BRHX]
Guaraldi, Giovanni; G., Orlando; G., Madeddu; F., Vescini; Ventura, Paolo; S., Campostrini; M. S., Mura; N., Parise; R., Caudarella; Esposito, Roberto...espandi
File in questo prodotto:
File Dimensione Formato  
GG HIV Clin Trials 2004.pdf

Solo gestori archivio

Tipologia: Versione pubblicata dall'editore
Dimensione 342.66 kB
Formato Adobe PDF
342.66 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/303981
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 65
social impact